{
  "id": "57180ae8e1112abf",
  "title": "IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines",
  "description": "20251215T184500Z",
  "content": "",
  "source": "pittsburghstar.com",
  "source_url": "http://www.pittsburghstar.com/news/278755986/igc-pharma-positions-as-a-singular-beneficiary-of-emerging-federal-momentum-toward-schedule-iii-cannabinoid-medicines",
  "published_at": "20251215T184500Z",
  "fetched_at": "2025-12-16T00:23:22.810654+00:00",
  "category": "health_biotech",
  "subcategory": null,
  "keywords": [],
  "location": "United States",
  "raw_data": {
    "url": "http://www.pittsburghstar.com/news/278755986/igc-pharma-positions-as-a-singular-beneficiary-of-emerging-federal-momentum-toward-schedule-iii-cannabinoid-medicines",
    "url_mobile": "",
    "title": "IGC Pharma Positions as a Singular Beneficiary of Emerging Federal Momentum Toward Schedule III Cannabinoid Medicines",
    "seendate": "20251215T184500Z",
    "socialimage": "",
    "domain": "pittsburghstar.com",
    "language": "English",
    "sourcecountry": "United States"
  }
}